Daniel O’Connell
Chief Executive Officer
Daniel O’Connell has over 20 years of venture creation, venture investment and start-up operations experience with a focus on neurosciences companies. He has served as president and chief executive officer of Acumen Pharmaceuticals, Inc., since December 2014. Under his leadership, Acumen has successfully transitioned from a privately held, pre-clinical biotech company to a publicly traded clinical-stage company developing a potential best-in-class treatment for early Alzheimer’s disease.
O’Connell previously cofounded and served as president and chief executive officer of Functional NeuroModulation Ltd., a clinical-stage company developing deep brain stimulation therapies for Alzheimer’s disease. O’Connell is a founding member and former managing partner of NeuroVentures Capital, LLC, a firm he helped to invest in emerging neurosciences companies. He earned a Bachelor of Arts from Brown University and a Master of Business Administration from the University of Virginia.